A Case Report On Abnormal Uterine Bleeding with Multi-System Disorders
LifeScience-Gynaecology
DOI:
https://doi.org/10.22376/ijlpr.2023.13.6.L182-L185Keywords:
Mixed connective tissue disease, auto-immune disorder, systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, auto-antibodies, antigen-antibody complex, antinuclear antibodiesAbstract
Autoimmune disease is a condition that attacks the immune system and leads to multi-system disorders like systemiclupus erythematosus and rheumatoid disorders, which initiates self-directed immune responses that result in clinical diseases,mainly in obstetrics conditions like recurrent pregnancy loss, pre-eclampsia are common. The study aimed to identify therelationship between connective tissue disorders and abnormal uterine bleeding patterns. A rare case of abnormal uterinebleeding with a past history of recurrent pregnancy loss was presented in the casualty with excessive menstrual bleeding in astate of hypovolemic shock. The patient complained of generalised malaise, giddiness, breathlessness, and palpitations for thepast 2 months. She suffered recurrent epistaxis for the past 2 months and experienced symptoms like loss of appetite, recurrentvomiting for the past 15 – 20 days, and rashes over the face and cheeks for 6 months. Her haemoglobin was 2.4g/dL, and theplatelets were less than 10,000 with bicytopenia at the time of admission She was shifted to ICU and haemodynamicallystabilized by packed red blood cells, fresh frozen plasma, and platelets. Following this, she was treated with antifibrinolytics, andsevere anaemia was corrected with multiple PRBC transfusions. Multiple single-donor platelet transfusions were also done. Afterrecovery, the patient was discharged with an advice to continue hydroxychloroquine. Immune dysregulation and inflammationtogether contribute to the development of menstrual disorders among women with Rheumatoid Disorders which can be wellmanaged with systematic therapeutic plans at the initial stage.
References
Atik RB, Christiansen OB, Elson J, Kolte AM, Lewis S, et al. hoy004. Hum Reprod Open. ESHREGuideline Group on RPL [ESHRE guideline]: recurrent pregnancy loss; 2018. doi: 10.1093/hropen/hoy004.
Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76(3):476-85. doi: 10.1136/annrheumdis-2016-209770.
Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-304. doi: 10.1136/annrheumdis-2019-215213, PMID 31092409.
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al.. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271-7. doi: 10.1002/art.1780251101. PMID 7138600.
Kaaja R, Julkunen H, Viinikka L, Ylikorkala O. Production of prostacyclin and thromboxane in lupus pregnancies: effect of small dose of aspirin. Obstet Gynecol. 1993;81(3):327-31. doi: 10.1016/0020-7292(93)90340. PMID 8437779.
Riera-Mestre A, Vidaller A. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018;379(13):1289-90. doi: 10.1056/NEJMc1808253, PMID 30260602.
Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.x. PMID 16420554.
Mackenzie AH. Antimalarial drugs for rheumatoid arthritis. Am J Med. 1983;75(6A):48-58. doi: 10.1016/0002-9343(83)90474-6, PMID 6362406.
Tsokos GC. Immunomodulatory treatment in patients with rheumatic diseases: mechanisms of action. Semin Arthritis Rheum. 1987;17(1):24-38. doi: 10.1016/0049-0172(87)90014-x. PMID 3306930.
Available from: https://www.niams.nih.gov/health-topics/autoimmune-diseases.
Angum F, Khan T, Kaler J, Siddiqui L, Hussain A. The Prevalence of Autoimmune Disorders in Women: a Narrative Review [review]. Cureus. 2020;12(5):e8094. doi: 10.7759/cureus.8094, PMID 32542149.
Luiro K, Holopainen E. Heavy Menstrual Bleeding in Adolescent: Normal or a Sign of an Underlying Disease? Semin Reprod Med. 2022;40(1-2):23-31. doi: 10.1055/s-0041-1739309. PMID 34734398.
Sapkota B, Al Khalili Y. Mixed connective tissuedisease. StatPearls [Internet]. Updated 2022Nov14:2023Jan-.
Aagaard-Tillery KM, Holmgren CM, James R. Scott; gynecologic problems in women with autoimmune diseases; reproductive and hormonal aspects of systemic. Autoimmune Dis. 2005;4:141-60.
Velo-García A, Castro SG, Isenberg DA. The diagnosis and management of the haematologic manifestations of lupus. J Autoimmun. 2016;74:139-60. doi: 10.1016/j.jaut.2016.07.001, PMID 27461045.
Fraser IS, Mansour D, Breymann C, Hoffman C, Mezzacasa A, Petraglia F. Prevalence of heavy menstrual bleeding and experiences of affected women in a European patient survey. Int J Gynaecol Obstet. 2015;128(3):196-200. doi: 10.1016/j.ijgo.2014.09.027, PMID 25627706.
Bruinvels G, Burden R, Brown N, Richards T, Pedlar C. The prevalence and impact of heavy menstrual bleeding (menorrhagia) in elite and non-elite athletes. PLoS One. 2016;11(2):e0149881. doi: 10.1371/journal.pone.0149881, PMID 26901873.
Published
How to Cite
Issue
Section
Copyright (c) 2023 Dr. Niranjani S, Dr. T.G. Revathy, Dr. Varrshine.R
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.